Literature DB >> 11426831

Characterisation of agonist binding on human 5-HT2C receptor isoforms.

K Quirk1, A Lawrence, J Jones, A Misra, V Harvey, H Lamb, D Revell, R H Porter, A R Knight.   

Abstract

The 5-HT2C receptor is expressed in different isoforms as a result of mRNA editing. Both INI (unedited) and VSV (a fully edited version) isoforms are abundant in rat brain. The VSV isoform lacks the high affinity recognition site for 5-HT, which may be caused by low efficiency coupling to G-proteins. In this study we have investigated the pharmacology of the agonist binding site of these two isoforms of the 5-HT2C receptor. The VSV isoform was expressed in Chinese hamster ovary cells (CHO) and the INI isoform in both Chinese hamster ovary cells and human embryonic kidney cells (HEK-293). Saturation analysis using [3H]5-HT revealed high and low affinity recognition sites on the INI isoform in both cell types whilst the VSV isoform did not have the high affinity binding site for [3H]5-HT. Displacement studies were undertaken using [3H]5-HT to label the receptors. In these studies the affinity of agonists (5-HT, Ro600175 ((S)-2-(6-Chloro-5-fluoroindol-1-yl)-1-methylethylamine), MK212 (6-Chloro-2-(piperazinyl) pyrazine), mCPP (1-(m-chlorophenyl)-piperazine), TfMPP (N-(m-trifluoromethylphenyl)piperazine), DOI (1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane), DOB (1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane) and 8OH-DPAT (8-hydroxy-2-(di-N-propylamino)tetralin) was higher at the INI isoform, whilst antagonist affinity (ketanserin and mesulergine) did not change between the two receptor isoforms. There were no differences between the INI isoform expressed in the CHO and HEK-293. This suggests that the INI isoform of the 5-HT2C receptor is pharmacologically similar to the VSV form of the 5-HT2C receptor but that it couples more efficiently to G-proteins.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11426831     DOI: 10.1016/s0014-2999(01)00943-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Serotonin 2c receptor RNA editing in major depression and suicide.

Authors:  Rebecca Lyddon; Andrew J Dwork; Mehdi Keddache; Larry J Siever; Stella Dracheva
Journal:  World J Biol Psychiatry       Date:  2012-03-09       Impact factor: 4.132

2.  Discriminative stimulus effects of serotonin agonists, neutral antagonists, and inverse agonists in pigeons: perspectives on intrinsic efficacy measurements in vivo.

Authors:  Martilias Farrell; Sharon Rosenzweig-Lipson; Ellen Walker
Journal:  Psychopharmacology (Berl)       Date:  2010-06-05       Impact factor: 4.530

3.  Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.

Authors:  Antony R Knight; Anil Misra; Kathleen Quirk; Karen Benwell; Dean Revell; Guy Kennett; Mike Bickerdike
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-30       Impact factor: 3.000

4.  Reduced hypophagic effects of d-fenfluramine and the 5-HT2C receptor agonist mCPP in 5-HT1B receptor knockout mice.

Authors:  Michelle D Lee; Elizabeth M Somerville; Guy A Kennett; Colin T Dourish; Peter G Clifton
Journal:  Psychopharmacology (Berl)       Date:  2004-05-08       Impact factor: 4.530

Review 5.  Fine-tuning serotonin2c receptor function in the brain: molecular and functional implications.

Authors:  Kelly A Berg; William P Clarke; Kathryn A Cunningham; Umberto Spampinato
Journal:  Neuropharmacology       Date:  2008-06-17       Impact factor: 5.250

6.  Neuronal differentiation induces SNORD115 expression and is accompanied by post-transcriptional changes of serotonin receptor 2c mRNA.

Authors:  Tomaž Bratkovič; Miha Modic; Germán Camargo Ortega; Micha Drukker; Boris Rogelj
Journal:  Sci Rep       Date:  2018-03-23       Impact factor: 4.379

7.  Editing of serotonin 2C receptor mRNA in the prefrontal cortex characterizes high-novelty locomotor response behavioral trait.

Authors:  Stella Dracheva; Rebecca Lyddon; Kevin Barley; Sue M Marcus; Yasmin L Hurd; William M Byne
Journal:  Neuropsychopharmacology       Date:  2009-06-03       Impact factor: 7.853

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.